Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Growth Metrics

Cresco Labs (CRLBF) Receivables (2019 - 2026)

Cresco Labs filings provide 6 years of Receivables readings, the most recent being $38.1 million for Q1 2026.

On a quarterly basis, Receivables changed N/A to $38.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $38.1 million, a N/A change, with the full-year FY2025 number at $37.9 million, changed N/A from a year prior.
Receivables hit $38.1 million in Q1 2026 for Cresco Labs, up from $37.9 million in the prior quarter.
In the past five years, Receivables ranged from a high of $59.0 million in Q4 2023 to a low of $37.9 million in Q4 2025.
Median Receivables over the past 5 years was $49.8 million (2024), compared with a mean of $48.8 million.